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b Blockers such as propranolol and labetalol are known to induce toxic myopathy
because of their partial b2 adrenoceptor agonistic effect. Nebivolol has the highest b1
receptor afﬁnity among b blockers, and it has never been reported to induce
rhabdomyolysis until now. We report a patient who developed rhabdomyolysis after
changing medication to nebivolol. A 75-year-old woman was admitted to our hos-
pital because of generalized weakness originating 2 weeks before visiting.
Approximately 1 month before her admission, her medication was changed from
carvedilol 12.5 mg to nebivolol 5 mg. Over this time span, she had no other lifestyle
changes causing rhabdomyolysis. Her blood chemistry and whole body bone scan
indicated rhabdomyolysis. We considered newly prescribed nebivolol as a causal
agent. She was prescribed carvedilol 12.5 mg, which she was previously taking,
instead of nebivolol. She was treated by hydration and urine alkalization. She had
fully recovered and was discharged.
Copyright © 2016. The Korean Society of Nephrology. Published by Elsevier. This is
an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
There are various causes of rhabdomyolysis. Recently, many
medicines and substances, including lipid-lowering drugs
(ﬁbrates and statins), alcohol, heroin, cocaine [1], diuretics,
antibiotics, and antifungal agents [2], have been reported as
causes of rhabdomyolysis.
Among antihypertensive agents, it has been reported that b
blockers, such as propranolol [3], labetalol [4], pindolol [5,6],
and xamoterol [6], can result in toxic myopathy, which induces
muscle cramps, pain, and muscle enzyme elevation.
Nebivolol is a selective b1-blocker with a nitric oxidee
potentiating vasodilatory effect in comparison with other b
blockers [7]. Nebivolol has a direct stimulatory effect onrtment of Internal Medi-
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ty of Nephrology. Published b
/4.0/).endothelial nitric oxide synthase, which results in increased
levels of local nitric oxide [8,9]. It has been reported that
nebivolol has an antioxidant effect [7,10]. In addition, there has
been no published report of nebivolol-induced rhabdomyolysis.
Although it is thought to have a more favorable side effect
proﬁle compared to other b blockers [11], nebivolol can
possibly induce rhabdomyolysis. We treated a patient who
developed rhabdomyolysis induced by nebivolol.Case report
A 75-year-old woman was admitted to our hospital because
of generalized weakness. The patient had been suffering from
generalized weakness and anorexia for 2 weeks and remotely
experienced symptom onset 1 month earlier. She had pain on
the right knee and right thigh but no respiratory or cardio-
vascular symptoms suggesting infectious disease such as
cough, sputum, rhinorrhea, sore throat, or fever. She had no
other lifestyle changes, including trauma history, severey Elsevier. This is an open access article under the CC BY-NC-ND license
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carvedilol 12.5 mg to nebivolol 5 mg 1 month before her
admission. She visited a private clinic, and her serum levels of
aspartate aminotransferase (AST) and alanine aminotransferase
(ALT) were elevated markedly. She was transferred to an
emergency room for further evaluation.
Previously, she was diagnosed with hypertension 11 years
ago and severe cardiovascular disease (3-vessel disease) treated
with a coronary artery bypass graft 4 years ago. She had taken
ﬂuvastatin 80 mg, valsartan 80 mg, aspirin 100 mg, and car-
vedilol 12.5 mg daily for 4 years. One month before her
admission, carvedilol was changed to nebivolol 5 mg daily. She
did not have diabetes mellitus, chronic hepatic disorder, or
chronic kidney disease. She was a housekeeper without a his-
tory of smoking, alcohol intake, or herbal medication.
On physical examination, the patient was obese (body mass
index, 26.57 kg/m2). Initial blood pressure was 136/66 mmHg.
The heart rate was 62 beats/min. The respiration rate was
20 breaths/min. Body temperature was 36.7C. Her mental
status was alert, and orientation was intact. She cannot stand
up on her own strength because of generalized weakness and
right knee pain. Muscle strength was decreased to Grade II on
the right lower leg and Grade IV on the other extremities and
trunk. No signiﬁcant tender point was found. Her urine was a
dark color when examined in the emergency room.
On the day of admission, her blood test disclosed the
following: AST 1,091 IU/L, ALT 913 IU/L, blood urea nitrogen
(BUN) 56.8 mg/dL, creatinine 1.3 mg/dL, lactate dehydrogenase
(LDH) 6,541 IU/L, creatine kinase (CK) 37,399 U/L, CK-MB
399.7 ng/mL, troponin I 0.15 ng/mL, erythrocyte sedimenta-
tion rate 54 mm/h, and C-reactive protein 1.0 mg/dL. The serumFigure 1. Tc-99m HDP bone scintigraphy. An increased tracer uptake was show
muscles.
HDP, hydroxymethane diphosphonate.myoglobin level was higher than the upper measurable range
(>3,000 ng/mL).
The levels of hemoglobin (13.3 g/dL), platelet (218,000/mL),
white blood cells (8,700/mL), total bilirubin (0.7 mg/dL), alkaline
phosphatase (106 IU/L), plasma sodium (141 mEq/L), potassium
(5.0 mEq/L), chloride (108 mEq/L), phosphorus (4.8 mg/dL), and
total calcium(9.4mg/dL) remained inthenormal range.Anarterial
blood gas analysis at this time revealed a pH of 7.37, PCO2
37 mmHg, PO2 87 mmHg, HCO3 21.4 mmol/L, and O2 saturation
96%.
The patient had the hepatitis B surface antibody. The results
of the test for a hepatitis B surface antigen, hepatitis C antibody,
reverse transcriptase-polymerase chain reaction of hepatitis C
RNA, human immunodeﬁciency virus antibody, and rapid
plasma reaginwere all negative. The test for hepatitis Awas not
performed in consideration of low incidence of hepatitis A in
her age.
The urine was strongly positive (þþþ) for blood in dipstick
test, but only 3e5/hours postfertilization (HPF) red blood cells
were present on microscopic examination. Other laboratory re-
sults include speciﬁc gravity 1.015, pH 5.5, protein (þþ), glucose
(e), ketone (e), bilirubin (e), urobilinogen (trace), nitrite (e),
many white blood cells, 2e3/HPF squamous epithelial cells.
There was no remarkable ﬁnding other than a simple cyst on
the right kidney on an abdominal ultrasonogram and a cardiac
echocardiogram. An electrocardiogram showed sinus rhythm
with normal intervals.
Technetium-99m hydroxymethane diphosphonate bone
scintigraphy showed increased tracer uptake in the abdominal
wall, both thighs, both deltoid muscles, and the right teres
muscles (Fig. 1).n in the abdominal wall, both thighs, both deltoid muscles, and right teres
Figure 2. Levels of CK (U/L), LDH (IU/L), AST (IU/L), and Cr (mg/dL) during
admission.
AST, aspartate aminotransferase; CK, creatine kinase; Cr, creatinine; LDH,
lactate dehydrogenase.
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arising from newly prescribed nebivolol. Prescription of nebi-
volol was stopped and changed to carvedilol 12.5 mg/d again.
She was admitted and treated by massive hydration and
urine alkalization. Altogether, 2 L of 5% dextrose saline solution
mixed with sodium bicarbonate (20 mEq/L) was administered.
We decided to observe for pyuria.
On the next day, reduction was observed in levels of CK
(30,430 IU/L), liver transaminases (AST 778 IU/L and ALT
749 IU/L), and LDH (5,137 IU/L). BUN (1.54 mg/dL) and
creatinine (1.54 mg/dL) levels were slightly elevated. On the
third admission day, BUN (50.3 mg/dL) and creatinine
(1.10 mg/dL) also showed decreases (Fig. 2).
On the sixthdayafteradmission, all theurinalysis resultswere
normal: speciﬁc gravity 1.011, pH 5.0, protein (e), erythrocyte
(e), 1e2/HPF red blood cells, and 0e1/HPF white blood cells.
On the 10th day after admission, the level of AST was
decreased to 28 IU/L and ALT to 94 IU/L. On the 12th day after
admission, her blood chemistry showed creatinine 0.8 mg/dL,
CK 138 U/L, and LDH 1,022 IU/L and her generalized weakness
had fully recovered.
On the 13th day after admission, the patient was discharged.
She was prescribed carvedilol 12.5 mg for b blocker, and all
other medications were continued as before.Discussion
Nowadays, b-adrenergic blocking agents are widely used
drugs for patients with various cardiovascular diseases such as
hypertension, angina, myocardial infarction, and heart failure
[12]. Many combinations of drugs recommended for patients
with cardiovascular disorders include b blockers, lipid-
lowering agents, antiplatelet agents, and angiotensin-
converting enzyme inhibitors and angiotensin II receptor
blockers are commonly included among the combinations. It is
well known that all the aforementioned drugs have been re-
ported as a cause of myopathy, especially the 3-hydroxy-3-
methylglutaryl coenzyme A reductase inhibitors.
The frequency of statin myopathy (including myalgia, mus-
cle weakness, and elevation of serum CK level) is differentamong various studies. Maron et al [13] described that myop-
athy with statin monotherapy occurs in ~1 of 1,000 patients
and is dose related. Ucar et al [14] analyzed the World Health
Organization's International Drug Information System database
and found myopathy to account for 0.02e1.8% of all adverse
reactions associated with 3-hydroxy-3-methylglutaryl coen-
zyme A reductase inhibitors and rhabdomyolysis to account for
0.2e2.1%.
Rhabdomyolysis is the most serious side effect of statin
therapy, in cases where renal insufﬁciency is already present.
However, in some studies, this side effect was found to be rare
(affecting 0.1% of statin users) [14,15], and no cases of drug-
related rhabdomyolysis were reported in some follow-up
studies [16,17]. Antons et al [18] reported that the incidence
rate of rhabdomyolysis during statin monotherapy was
0.0042% per 1 year of therapy. Alsheikh-Ali et al [19] demon-
strated that a rate of rhabdomyolysis in a high-dose simvastatin
(80 mg) trial [20] was more than 7-fold higher than that in
intermediate-dose simvastatin (40 mg) trials (67 vs. 9 cases of
rhabdomyolysis per 100,000 person-years), but the risk of
rhabdomyolysis was not increased in clinical trials of other
high-dose statins (lovastatin 80 mg, simvastatin 80 mg, ﬂu-
vastatin 80 mg, and atorvastatin 80 mg).
When we focused on b blockers, we found that many side
effects of b blockers were already reported. Side effects, such as
bradycardia, hypotension, orthostatic hypotension, malaise,
dizziness, occur commonly in clinical situations. The main side
effects of b blockers, such as myocardial depression and hy-
potension, are caused by their excessive therapeutic effects,
leading to tissue hypoperfusion. There are case reports of
complications with b-blocker ingestion including mesenteric
ischemia [21], acute renal failure [22], and rhabdomyolysis [23].
It was also reported that toxic myopathy resulted from b
blockers such as propranolol, labetalol, pindolol, and xamoterol
[3e6]. The rise in the CK level or muscle cramps occur more
frequently with pindolol than propranolol and may be related
to the partial b-adrenergic receptor agonist activity. Mechanism
of this elevation of CKwith pindolol is unclear but appears to be
due to increased permeability of the cell membrane and the
density and reactivity of the b2 adrenoceptors on the mem-
brane [6]. Skeletal muscle contains a signiﬁcant proportion of
b2 adrenoceptors, but there are also 7e10% of b1 adrenoceptors
and a smaller proportion of a adrenoceptors [24]. Some b2
agonists could increase skeletal muscle mass by regulation of
protein synthesis, gene transcription, and apoptosis [24], but
pure b2 agonists may cause muscle cramps [25]. Xamoterol is a
selective b1 adrenoceptor agonist, which has stimulatory effect
on sinoatrial and atrioventricular nodes of the heart. The
absence of any rise in CK levels during treatment with or after
withdrawal of xamoterol would suggest that the CK response
may be due to speciﬁc b2 adrenoceptor partial agonism [6].
Generally, nebivolol is thought to have a more favorable side
effect proﬁle than other b blockers. Van Bortel et al [11]
demonstrated that tolerability between nebivolol and
angiotensin-converting enzyme inhibitors was similar, but
nebivolol had better tolerability than other b blockers, calcium
channel antagonists, and the angiotensin II receptor antagonists,
including losartan, by analyzing data from 8 studies comparing
nebivolol with other antihypertensive drugs. In a meta-analysis
of 10 trials comparing nebivolol with atenolol, bisoprolol, and
metoprolol, nebivolol showed few adverse events and drug
withdrawals while exhibiting similar efﬁcacy [26].
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did not occur while taking carvedilol in this patient. Although
the mechanism responsible for nebivolol-induced rhabdo-
myolysis is unclear, there are several reported differences be-
tween nebivolol and carvedilol that are useful to estimate the
possible causes.
Carvedilol is a comprehensive b blocker that blocks b1, b2,
and a receptors in the heart [27]. b1eselective b blockers
upregulate b1 receptor density and increase b1 receptor sensi-
tivity to adrenergic stimulation; this has not been seen with
carvedilol [28].
Nebivolol has the highest b1 receptor afﬁnity among b
blockers, and a-blocking properties, and agonistic activity on b3
receptors [8]. It also has vasodilating properties attributed to its
interactionwith the L-arginine nitric oxide pathway, a property
not shared by other b blockers [29]. That is the reason why
nebivolol led to a greater reduction of diastolic blood pressure
than carvedilol although they demonstrated similar efﬁcacy on
systolic blood pressure reduction [30]. Produced via 2-step
oxidation of L-arginine, nitric oxide has potent antiathero-
sclerotic properties and inhibitory effect on the proliferation of
smooth muscle cells in high concentrations [8].
There is a possibility that rhabdomyolysis was induced by
the agonistic activity on b3 receptors of nebivolol. Sprague et al
[31,32] demonstrated that carvedilol reverses hyperthermia
and subsequent rhabdomyolysis induced by 3,4-
methylenedioxy-methamphetamine (MDMA, ecstasy) in an
animal model. MDMA-induced hyperthermia is commonly
associated with skeletal muscle breakdown, rhabdomyolysis,
and renal failure. The mechanism of MDMA-induced hyper-
thermia is considered to be a combination of the following: a-1
adrenoceptor activation resulting in thermogenesis and
visceral vasoconstriction to divert blood to skeletal muscle, b3
adrenoceptor activation resulting in skeletal muscle thermo-
genesis, and activation of the skeletal muscle thermogenic
protein, uncoupling protein-3. Carvedilol blocks these re-
ceptors so that it attenuates MDMA-induced CK release.
As far as we know, this is the ﬁrst published case of
nebivolol-induced rhabdomyolysis. In previously reported
cases of rhabdomyolysis, there is only one patient who was
indicated to have been taking a combination of drugs including
nebivolol. Medications other than nebivolol were thought to be
the causative agent in these cases [33].
Our case report shows the possibility of myotoxicity with
nebivolol. The patient had taken carvedilol as a b blocker for 56
months and ﬂuvastatin for 32 months, but her symptom
occurred about 2 weeks after changing medication from car-
vedilol to nebivolol. Furthermore, she had completely recov-
ered after hydration and restoring her medication to carvedilol.
Moreover, the patient remained free from other complications
of drugs, such as myopathy, for 9 months through to her most
recent follow-up. These sequential events are enough to arouse
suspicion that nebivolol has a causal relationship with
rhabdomyolysis.
The amount of creatinine elevation (up to 1.5 mg/dL) was
mild although the level of CK (37,399 U/L), AST (1,091 IU/L), and
ALT (913 IU/L) was highly elevated in this case. We were unable
to analyze a clinical difference between this case and other case
reports of b blockereinduced rhabdomyolysis in detail because
of the small number of cases.
Looking back in the case of this patient, we should also
consider the possibility that rhabdomyolysis was induced bythe interaction of nebivolol and other previously administered
drugs such as ﬂuvastatin. Omar et al [34] found that statin
drugs alone or in combination therapy can cause rhabdo-
myolysis. Wagner et al [35] conducted an in vitro study and
reported that combination treatment with propranolol and
statins causes additive muscle toxicity in a dose-dependent
manner, but the cohort study conducted by Setoguchi et al
[3] found no evidence of a synergistic effect between the use of
propranolol and statins in causing myopathy.
The patient was admitted in February which was the ﬂu
season, so we should also consider the possibility of infection-
induced rhabdomyolysis in addition to medication. The most
common viral etiology of rhabdomyolysis is inﬂuenza virus,
followed by human immunodeﬁciency virus, Coxsackie virus,
and EpsteineBarr virus, and the most common bacterial or-
ganisms are Legionella species, followed by Francisella tular-
ensis, Streptococcus species, and Salmonella species [36]. The
patient did not present any symptoms or signs to suspect an
infection such as fever, chills, sore throat, cough, sputum, rhi-
norrhea, diarrhea, or abdominal pain. Therefore it was
considered that there was no need for additional tests to rule
out other respiratory or gastrointestinal infection.
Her technetium-99m hydroxymethane diphosphonate bone
scintigraphy showed increased tracer uptake not only in the
weakened right thigh but also the muscles of the trunk, which
had no remarkable symptom. Soft tissue uptake at bone scin-
tigraphy can be found because of benign (myositis
ossiﬁcans and tumoral calcinosis) and malignant (osteogenic
sarcomas and adenocarcinomas) calciﬁcation, inﬂammation
(polymyositis and soft tissue infection), and increased physical
exercise [37e40]. There was no extraosseous calciﬁcation on
her chest X-ray examination and no leukocytosis, focal ery-
thema, or tenderness suggesting inﬂammation. She recovered
only with massive hydration without administration of anti-
biotics or immunosuppressants, and her muscle weakness has
not recurred in the 17-month follow-up period. It is suspected
that the cause of the increased tracer uptake in the trunk is the
increased use of muscles of the trunk and upper extremity due
to the weakness in the right leg or personal habits of the
patient.
In summary, nebivolol, a third-generation b blocker, has
been in the limelight as a relatively safe antihypertensive agent
so far, but there is a possibility of it causing rhabdomyolysis
when taken alone or in combination with other agents. There-
fore, when a patient taking nebivolol is suspected to be affected
by myopathy or rhabdomyolysis, nebivolol should be consid-
ered as a potential culprit and be discontinued if possible.Conﬂicts of interest
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